


REMARKS

Election/Restrictions

In response to the Restriction Requirement dated December 11, 2007, Applicants elect Group I, claims 1-8 drawn to methods for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation comprising administering an inhibitor.

For the species, we designate Compound (I) disclosed on page 6 of the specification, namely: 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide having the formula I




Further from Claim 1, Applicants designate the species c-Kit from the list in claim 1.

From claim 3, Applicants designate the compound 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

With regard to Claim 6, Applicants designate the disease being Alzheimer's.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898
Date: February 4, 2008

Respectfully submitted,

A handwritten signature in cursive script, reading "Lydia T. McNally", written over a horizontal line.

Lydia T. McNally
Attorney for Applicant
Reg. No. 36,214